These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37072054)

  • 41. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
    Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants.
    Alcantara MC; Higuchi Y; Kirita Y; Matoba S; Hoshino A
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia.
    Alshukairi AN; Aldabbagh Y; Adroub SA; Mourier T; Abumelha KY; Albishi GE; Alraddadi BM; Al Hroub MK; El-Saed A; Ibrahim SMN; Al Musawa M; Almasari A; Habahab WT; Alhamlan FS; Al-Omari A; Pain A; Dada A
    J Epidemiol Glob Health; 2023 Mar; 13(1):47-54. PubMed ID: 36626091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.
    Ward T; Glaser A; Overton CE; Carpenter B; Gent N; Seale AC
    Epidemiol Infect; 2022 Dec; 151():e32. PubMed ID: 36535802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
    Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment.
    Chen CS; Jian MJ; Chang CK; Chung HY; Li SY; Lin JC; Yeh KM; Yang YS; Chen CW; Hsieh SS; Tang SH; Perng CL; Chang FY; Shang HS
    PeerJ; 2023; 11():e14666. PubMed ID: 36710871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.
    Davies MA; Morden E; Rousseau P; Arendse J; Bam JL; Boloko L; Cloete K; Cohen C; Chetty N; Dane P; Heekes A; Hsiao NY; Hunter M; Hussey H; Jacobs T; Jassat W; Kariem S; Kassanjee R; Laenen I; Roux SL; Lessells R; Mahomed H; Maughan D; Meintjes G; Mendelson M; Mnguni A; Moodley M; Murie K; Naude J; Ntusi NAB; Paleker M; Parker A; Pienaar D; Preiser W; Prozesky H; Raubenheimer P; Rossouw L; Schrueder N; Smith B; Smith M; Solomon W; Symons G; Taljaard J; Wasserman S; Wilkinson RJ; Wolmarans M; Wolter N; Boulle A
    Int J Infect Dis; 2023 Feb; 127():63-68. PubMed ID: 36436752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
    Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA
    medRxiv; 2022 Jan; ():. PubMed ID: 35043117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case-case study based on electronic health records.
    Kislaya I; Peralta-Santos A; Borges V; Vieira L; Sousa C; Ferreira B; Pelerito A; Gomes JP; Leite PP; Nunes B; ; Machado A; Rodrigues AP; Peixoto VR; Casaca P; Fernandes E; Rodrigues E; Ferreira R; Isidro J; Pinto M; Duarte S; Santos D; Meneses L; Almeida JP; Matias A; Freire S; Grilo T
    Influenza Other Respir Viruses; 2023 Mar; 17(3):e13121. PubMed ID: 36935845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
    Link-Gelles R; Levy ME; Gaglani M; Irving SA; Stockwell M; Dascomb K; DeSilva MB; Reese SE; Liao IC; Ong TC; Grannis SJ; McEvoy C; Patel P; Klein NP; Hartmann E; Stenehjem E; Natarajan K; Naleway AL; Murthy K; Rao S; Dixon BE; Kharbanda AB; Akinseye A; Dickerson M; Lewis N; Grisel N; Han J; Barron MA; Fadel WF; Dunne MM; Goddard K; Arndorfer J; Konatham D; Valvi NR; Currey JC; Fireman B; Raiyani C; Zerbo O; Sloan-Aagard C; Ball SW; Thompson MG; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(29):931-939. PubMed ID: 35862287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SARS-CoV-2 Omicron (BA.4, BA.5) variant: Lessons learned from a new variant during the COVID-19 pandemic.
    Erabi G; Faridzadeh A; Parvin A; Deravi N; Rahmanian M; Fathi M; Aleebrahim-Dehkordi E; Rezaei N
    Health Sci Rep; 2024 Feb; 7(2):e1873. PubMed ID: 38332930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outpatient treatment options to address the SARS-CoV-2 variant Omicron.
    McCarthy MW
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1129-1133. PubMed ID: 35549623
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.